The city of Hartford, Connecticut, currently has 2 active clinical trials seeking participants for Crohn's Disease research studies.
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Recruiting
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: A 12-week induction period A maintenance period from Week 12 to Week 52, and A safety follow-up period up to... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/17/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Crohn's Disease
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits.
Gender:
All
Ages:
Between 2 years and 19 years
Trial Updated:
05/27/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease